These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 30235244)

  • 1. No difference in effectiveness of treatment simplification to boosted or unboosted atazanavir plus lamivudine in virologically suppressed in HIV-1-infected patients.
    Gutierrez-Valencia A; García C; Viciana P; Milanés-Guisado Y; Fernandez-Magdaleno T; Espinosa N; Pasquau J; López-Cortés LF
    PLoS One; 2018; 13(9):e0203452. PubMed ID: 30235244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of atazanavir-containing antiretroviral regimens, with or without ritonavir, in patients who are HIV-positive and treatment-naïve.
    Bertz RJ; Persson A; Chung E; Zhu L; Zhang J; McGrath D; Grasela D
    Pharmacotherapy; 2013 Mar; 33(3):284-94. PubMed ID: 23456732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid drug concentrations and viral suppression in HIV-1-infected patients receiving ritonavir-boosted atazanavir plus lamivudine dual antiretroviral therapy (Spanish HIV/AIDS Research Network, PreEC/RIS 39).
    Imaz A; Niubó J; Amara A; Khoo S; Ferrer E; Tiraboschi JM; Acerete L; Garcia B; Vila A; Podzamczer D
    J Neurovirol; 2018 Aug; 24(4):391-397. PubMed ID: 29542028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M).
    Di Giambenedetto S; Fabbiani M; Quiros Roldan E; Latini A; D'Ettorre G; Antinori A; Castagna A; Orofino G; Francisci D; Chinello P; Madeddu G; Grima P; Rusconi S; Di Pietro M; Mondi A; Ciccarelli N; Borghetti A; Focà E; Colafigli M; De Luca A; Cauda R;
    J Antimicrob Chemother; 2017 Apr; 72(4):1163-1171. PubMed ID: 28093483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unboosted atazanavir plus co-formulated lamivudine/abacavir as a ritonavir-sparing simplification strategy in routine clinical practice.
    Santos JR; Moltó J; Llibre JM; Pérez N; Capitán ; Miranda C; Clotet B
    HIV Clin Trials; 2009; 10(3):129-34. PubMed ID: 19632951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir.
    Gianotti N; Seminari E; Guffanti M; Boeri E; Villani P; Regazzi M; Bigoloni A; Schira G; Tiberi S; Fusetti G; Lazzarin A; Castagna A
    New Microbiol; 2005 Apr; 28(2):119-25. PubMed ID: 16035256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ARIES 144 week results: durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudine.
    Squires KE; Young B; DeJesus E; Bellos N; Murphy D; Ward D; Zhao HH; Ross LL; Shaefer MS;
    HIV Clin Trials; 2012; 13(5):233-44. PubMed ID: 23134624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.
    Squires KE; Young B; Dejesus E; Bellos N; Murphy D; Zhao HH; Patel LG; Ross LL; Wannamaker PG; Shaefer MS;
    AIDS; 2010 Aug; 24(13):2019-27. PubMed ID: 20613461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study.
    Mondi A; Fabbiani M; Ciccarelli N; Colafigli M; D'Avino A; Borghetti A; Gagliardini R; Cauda R; De Luca A; Di Giambenedetto S
    J Antimicrob Chemother; 2015; 70(6):1843-9. PubMed ID: 25885326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.
    Perez-Molina JA; Rubio R; Rivero A; Pasquau J; Suárez-Lozano I; Riera M; Estébanez M; Santos J; Sanz-Moreno J; Troya J; Mariño A; Antela A; Navarro J; Esteban H; Moreno S;
    Lancet Infect Dis; 2015 Jul; 15(7):775-84. PubMed ID: 26062881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: A prospective cohort study.
    Llibre JM; Cozzi-Lepri A; Pedersen C; Ristola M; Losso M; Mocroft A; Mitsura V; Falconer K; Maltez F; Beniowski M; Vullo V; Hassoun G; Kuzovatova E; Szlavik J; Kuznetsova A; Stellbrink HJ; Duvivier C; Edwards S; Laut K; Paredes R;
    Medicine (Baltimore); 2016 Oct; 95(40):e5020. PubMed ID: 27749561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients.
    Malan DR; Krantz E; David N; Wirtz V; Hammond J; McGrath D;
    J Acquir Immune Defic Syndr; 2008 Feb; 47(2):161-7. PubMed ID: 17971713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study).
    Di Giambenedetto S; Fabbiani M; Colafigli M; Ciccarelli N; Farina S; Sidella L; D'Avino A; Mondi A; Cingolani A; Tamburrini E; Murri R; Navarra P; Cauda R; De Luca A
    J Antimicrob Chemother; 2013 Jun; 68(6):1364-72. PubMed ID: 23372058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients.
    Santoro MM; Bertoli A; Lorenzini P; Ceccherini-Silberstein F; Gianotti N; Mussini C; Torti C; Di Perri G; Barbarini G; Bini T; Melzi S; Caramello P; Maserati R; Narciso P; Micheli V; Antinori A; Perno CF;
    Infection; 2009 Jun; 37(3):233-43. PubMed ID: 19169632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients.
    Squires KE; Young B; DeJesus E; Bellos N; Murphy D; Sutherland-Phillips DH; Zhao HH; Patel LG; Ross LL; Wannamaker PG; Shaefer MS;
    HIV Clin Trials; 2010; 11(2):69-79. PubMed ID: 20542844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, tolerability and virological consequences of long-term use of unboosted atazanavir plus 2 NRTIs in HIV-infected patients.
    Bonora S; Calcagno A; Vigano O; Bigliano P; Marinaro L; Colella E; Orofino G; Trentini L; Tettoni MC; D'Avolio A; Mercadante S; Galli M; Di Perri G; Rusconi S
    Curr HIV Res; 2014; 12(5):339-46. PubMed ID: 25106410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy.
    Belmonti S; Lombardi F; Quiros-Roldan E; Latini A; Castagna A; Borghetti A; Baldin G; Ciccullo A; Cauda R; De Luca A; Di Giambenedetto S;
    J Antimicrob Chemother; 2018 Jul; 73(7):1949-1954. PubMed ID: 29788156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical Practice.
    Gantner P; Bani-Sadr F; Garraffo R; Roger PM; Treger M; Jovelin T; Pugliese P; Rey D;
    PLoS One; 2016; 11(10):e0164240. PubMed ID: 27798641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment response to unboosted atazanavir in combination with tenofovir disoproxil fumarate and lamivudine in human immunodeficiency virus-1-infected patients who have achieved virological suppression: A therapeutic drug monitoring and pharmacogenetic study.
    Tsai MS; Chang SY; Lin SW; Kuo CH; Sun HY; Wu BR; Tang SY; Liu WC; Su YC; Hung CC; Chang SC
    J Microbiol Immunol Infect; 2017 Dec; 50(6):789-797. PubMed ID: 26857335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unboosted atazanavir with lamivudine/emtricitabine for patients with long-lasting virological suppression.
    Carbone A; Galli L; Bigoloni A; Bossolasco S; Guffanti M; Maillard M; Carini E; Salpietro S; Spagnuolo V; Gianotti N; Lazzarin A; Castagna A
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19811. PubMed ID: 25397555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.